BFRIBiofrontera Inc.

Is Biofrontera struggling financially?

Yes, by its own account. Biofrontera told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$22.0M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 5months

    If it eases off

    Empty by Nov 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$4.7M

÷

Cash burned over the last 12 months

$15.2M

What Biofrontera told the SEC

…and maintaining the business strategy for a period of twelve months from the issuance date of this report. Management believes that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. The Company plans to address the conditions that raise substantial doubt regarding its ability…

Biofrontera Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 35.1% share-count increase The company issued stock. Each share now owns 26.0% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 30% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt